Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Participation Type:

HIVR4P Home

HIVR4P 2016 is made possible in part by the generous support of the American people through 1 R13 AI122959-01 from the National Institute of Allergy and Infectious Diseases (NIAID), and from the United States Agency for International Development (USAID). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services or USAID; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 13 of 13 from HIV Research for Prevention 2016
Plenary 03: Which Way Is Forward: Emerging Challenges and Opportunities
Progress in Neutralizing Antibody-based HIV Vaccine Design
Dennis Burton
The Scripps Research Institute, United States
A View from the Ground
Noel Gordon
Human Rights Campaign, United States
Rings and Things
Sharon Hillier
University of Pittsburgh, United States
from HIV Research for Prevention 2016 on 19 October 2016 08:30-10:00
Oral Abstract Session 09: HIV Antibodies: The Good, the Bad and the Ugly
Characterization of the Early Antibody Landscape in HIV-1 Infected Individuals Who Develop Poor to Elite Levels of Neutralization Breadth
S. Abigail Smith
Emory University, United States
HIV-1 Superinfection Can Lead to Potent Neutralization of the Superinfecting Virus but Is Not Sufficient to Elicit Broadly Neutralizing Antibodies
Daniel J Sheward
University of Cape Town, South Africa
Characterization of Broadly Neutralizing Antibody Responses in HIV-1 Subtype C Infected Children
Zanele Ditse
National Institute for Communicable Diseases of the National Health Laboratory Service, South Africa
The Intrinsic Mutability of Antibody Variable Gene Is Critical for Reproducing Similar Mutation Signatures
Zizhang Sheng
Columbia University Medical Center, United States
Structure of a CH58-like V2 Antibody from Natural Infection Reveals Convergent Heavy Chain Maturation and a Novel K169 Binding Light Chain Motif
Constantinos Kurt Wibmer
National Institute for Communicable Diseases (NHLS), South Africa
Structure of a Natively-glycosylated HIV-1 Env Reveals a New Mode for VH1-2 Antibody Recognition of the CD4 Binding Site Relevant to Vaccine Design
Harry Gristick
Caltech, United States
from HIV Research for Prevention 2016 on 19 October 2016 10:30-12:00
Oral Abstract Session 10: Back to the Future: Optimizing the Cascade
Looking at the Whole Picture: The HIV Testing and Care Continuum among Community-recruited MSM, IDU, and Heterosexuals in Washington, DC, 2007-2015
Rudy Patrick
George Washington University Milken Institute School of Public Health, United States
High Uptake of Antiretroviral Treatment among Female Sex Workers in Kigali, Rwanda
Etienne Karita
Project San Francisco, Rwanda
Acceptability of a New Smartphone-based HIV and Syphilis Test to Screen Sexual Partners among High Risk MSM and Transgender Women
Iván Balán
New York State Psychiatric Institute and Columbia University, United States
Potential Impact on HIV Incidence of Increasing Viral Suppression among HIV-positive MSM in Baltimore: Mathematical Modelling for HPTN 078
Kate M. Mitchell
Imperial College London, United Kingdom
Detectable Viral Loads among Those Who Self-report Being Undetectable in the RADAR Cohort of Young MSM - Implications for Treatment as Prevention
Brian Mustanski
Northwestern University, United States
Using Peer Educators to Scale-up HIV Oral Self-testing among Female Sex Workers: An Implementation Science Approach from Kenya
Kipruto Chesang
U.S. Centers for Disease Control and Prevention, Kenya, Kenya
from HIV Research for Prevention 2016 on 19 October 2016 10:30-12:00
Oral Abstract Session 11: Testing Vaccine Concepts: Where the Rubber Hits the Road
First-in-human Clinical Trial Evaluating Mosaic HIV-1 Immunogens
Lindsey R Baden
Brigham and Women's Hospital/Harvard Medical School, United States
Optimization of a Pediatric Vaccine to Prevent Breast Milk Transmission of HIV-1
Bonnie Phillips
University of North Carolina at Chapel Hill, United States
DNA and Protein Co-delivery Vaccines Using TLR-4-based Adjuvants Induce Potent Immune Responses Able to Delay Heterologous SIV Acquisition
Barbara K. Felber
National Cancer Institute at Frederick, United States
DNA and Protein Co-administration Elicits Higher HIV-specific nAb and Comparable CD4+ T-cell Responses as Traditional Prime/Boost Regimens (HVTN 105)
Nadine Rouphael
Emory University, United States
Protective Efficacy of Candidate Clinical HIV-1 Vaccine Regimens Against SHIV-SF162P3 Challenges in Rhesus Monkeys
Frank Wegmann
Crucell Holland B.V., a Janssen pharmaceutical company of Johnson & Johnson, Netherlands
Comparing Different Priming Strategies to Optimize HIV Vaccine Antibody Responses: Results from HVTN 096/EV04 (NCT01799954)
Giuseppe Pantaleo
Swiss Vaccine Research Institute, Switzerland
from HIV Research for Prevention 2016 on 19 October 2016 10:30-12:00
Oral Abstract Session 12: Pipelines and Platforms for Prevention
Ranpirnase Exhibits Dose-dependent Inhibition of Rectal Explant Infection with HIV-1
Ian McGowan
University of Pittsburgh, United States
Development and Proof-of-Concept Clinical Evaluation of a Freeze-dried Topical Microbicide Insert for On-demand HIV Prevention
Wei Zhang
CONRAD, Eastern Virginia Medical School, United States
Foamed Silicone Intravaginal Rings for Delivery of Macromolecular Therapeutics
Matthew A. Petersen
ProMed Pharma, United States
A Single-reservoir Microbicide Intravaginal Ring for Dual Delivery of Tenofovir and Elvitegravir
Alexander Evanoff
Northwestern University, United States
Evaluation of MK-2048 and Vicriviroc, Formulated as Single or Combination (MK-2048A) Intravaginal Rings, for Development as a Vaginal Microbicide
Charlene Dezzutti
University of Pittsburgh, United States
ECLAIR Study of Cabotegravir LA Injections: Characterization of Safety and PK During the “PK Tail” Phase
Susan Ford
PAREXEL International, United States
from HIV Research for Prevention 2016 on 19 October 2016 10:30-12:00
Oral Abstract Session 13: Do Right to Do Well: Creating a Framework for Success
Harmonization of Regulatory Framework for Control of Clinical Trials in East Africa: Progress, Challenges and Lessons Learnt
Jane Humphrey Mashingia
East African Community Secretariat, Tanzania, United Republic of
Ethics Research to Inform Sexual and Gender Minority Adolescent Participation in HIV Prevention Research
Kathryn Macapagal
Northwestern University, United States
The Journey to GPP Implementation for KAVI Institute of Clinical Research
Jane Ng'ang'a
KAVI-Institute of Clinical research, University of Nairobi, Kenya
Improving the Efficiency of African Research Ethics Committees and Standardizing Ethics Review Processes - Through an Automated Review Platform
Boitumelo Mokgatla
International AIDS Vaccine Initiative (IAVI), Botswana
Toward Innovation in HIV Prevention: Sustaining Funding in a Post-2015 Landscape
Laura Marie Lazar
AVAC: Global Advocacy for HIV Prevention, United States
From Research to Policy to Implementation: A National Plan for Couples' Voluntary HIV Counseling and Testing (CVCT) in Zambia
Susan Allen
Rwanda Zambia HIV Research Group-Emory University, United States
from HIV Research for Prevention 2016 on 19 October 2016 13:00-14:30
Oral Abstract Session 14: Teaching the Immune System New Tricks: Vaccine-Induced Immune Responses
Ex Vivo Evaluation of Mucosal Cytokine Responses to in Vivo Vaccination with ALVAC-HIV/AIDSVAX® B/E of Non-human Primates (NHPs) and Humans
Carolina Herrera
Imperial College London, United Kingdom
Vaccine-induced Antibody that Captures but Does Not Neutralize SIVmac251 Increases the Rate of Infection after Low-dose, Repeated Rectal Challenge
Johannes S. Gach
University of California Irvine, United States
NK Cell Changes after a Late Boost with ALVAC-HIV and AIDSVAX® B/E in HIV-Uninfected Thai Adults from RV144
Michael A. Eller
U.S. Military HIV Research Program, Walter Reed Army Institute of Research, United States
The Relationship between Immune Responses to Tetanus Vaccine, Hepatitis B Vaccine and a Pox-protein HIV Vaccine Regimen
Ying Huang
Fred Hutchinson Cancer Research Center, United States
Broad HIV-1 Inhibition in Vitro by Vaccine-elicited CD8+ T Cells in African Adults
Josephine Cox
International AIDS Vaccine Initiative (IAVI), United States
Antibody Signature-based Design of HIV-1 Env gp140 Expands Tier 2 Neutralizing Antibody Breadth in Guinea Pigs
Christine Bricault
Beth Israel Deaconess Medical Center, Harvard Medical School, United States
from HIV Research for Prevention 2016 on 19 October 2016 13:00-14:30
Oral Abstract Session 15: Unique and Essential: Mucosal Environment of the Female Reproductive Tract
Differences in Genital Tract Immune Cell Populations and Innate Cervicovaginal Fluid Anti-HIV Activity among Women from Zimbabwe and the United States
Sharon L. Achilles
University of Pittsburgh, United States
Very Early Mucosal Responses to Vaginal Infection of SIV
Liang Shang
University of Minnesota, United States
Characterization of Dendritic Cells with Rapid HIV Capture Potential from the Human Female Reproductive Tract
Marta Rodriguez-Garcia
Geisel School of Medicine at Dartmouth, United States
Influence of Sex Hormones and Hormonal Contraceptives on Markers of HIV Risk in the Adolescent Female Genital Tract
Smritee Dabee
University of Cape Town, South Africa
Longitudinal Combined Immunomodulatory Effects of Hormonal Contraceptives and Cervicovaginal Infections in Women Who Did or Did Not HIV Seroconvert
Charles Morrison
FHI 360, United States
Inflammatory Cytokine Responses in the Lower Female Reproductive Tract in Response to Semen
Sinaye Ngcapu
Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa
from HIV Research for Prevention 2016 on 19 October 2016 13:00-14:30
Oral Abstract Session 16: PrEP and the Real World
PrEP Initiation and Early Adherence among Young MSM and Transgender Women in Chicago in the Enhancing PrEP in Community (EPIC) Study
Albert Liu
San Francisco Department of Public Health, United States
PrEP Adherence among East African Women with HIV-infected Partners Participating in an Open-label Study
Maria Pyra
University of Washington, United States
PrEP Implementation by Local Health Departments in US Cities and Counties: Findings from a 2015 Assessment of Local Health Departments
Dawn Smith
Centers for Disease Control and Prevention, United States
Women's Knowledge of, Interest in, and Eligibility for HIV Pre-exposure Prophylaxis at Family Planning Clinics in Northern California
Dominika Seidman
University of California San Francisco, United States
Feasibility and Uptake of HIV Self-testing among Adults Visiting Community Pharmacies in Kenya
Peter Mugo
Kemri-Wellcome Trust Research Programme, Kenya
Unplanned Discontinuations of HIV Pre-exposure Prophylaxis During Clinical Care
Douglas Krakower
Beth Israel Deaconess Medical Center, United States
from HIV Research for Prevention 2016 on 19 October 2016 13:00-14:30
Round Table 01: What Is Sterilizing Immunity?
Factors that Impact on the Genotypic and Phenotypic Features of Heterosexually Transmitted Clade C Founder Viruses
Carolyn Williamson
University of Cape Town & NHLS, South Africa
Early Events in HIV-1 Infection: New Insight from the RV217 Early Capture Acute Infection Cohort
Gustavo Kijak
U.S. Military HIV Research Program, Walter Reed Army Insititute of Research, United States
Breakthrough Occult HIV Infections Despite Sustained Plasma Levels of Antiretroviral Drugs Delivered in Long-acting Formulations
Martina Kovarova
University of North Carolina at Chapel Hill, United States
Gp120 Signatures Determining HIV Infectivity Are Universal across Primate Lentiviruses
Mileidy Gonzalez
NCBI, NIH, United States
Neutralizing Antibody-mediated Protection against Mucosal SHIV Challenge Includes Systemic Clearance of Distal Virus
Dan Barouch
Beth Israel Deaconess Medical Center, United States
Round Table Discussion: What Is Sterilizing Immunity?
Carolyn Williamson
University of Cape Town & NHLS, South Africa
Gustavo Kijak
U.S. Military HIV Research Program, Walter Reed Army Insititute of Research, United States
Martina Kovarova
University of North Carolina at Chapel Hill, United States
Mileidy Gonzalez
NCBI, NIH, United States
Dan Barouch
Beth Israel Deaconess Medical Center, United States
from HIV Research for Prevention 2016 on 19 October 2016 15:30-17:00
Round Table 02: The PrEP Prevention Package: From Efficacy Studies to the Real World
Case Studies in PrEP Implementation: The Australian Expanded PrEP Implementation in Communities Study (EPIC-NSW)
Andrew Grulich
Kirby Institute, UNSW Australia, Australia
Pre-Exposure Prophylaxis (PrEP): NYC Implementation Strategy
Demetre Daskalakis
New York City Department of Health and Mental Hygiene, United States
Structural Interventions to Enhance PrEP Availability and Delivery
Nduku Kilonzo
National AIDS Control Council, Kenya
Key Populations and Young People Views and Experiences on PrEP. Messages for Advocacy
Matteo Cassolato
International HIV/AIDS Alliance
Round Table Discussion: The PrEP Prevention Package: From Efficacy Studies to the Real World
Andrew Grulich
Kirby Institute, UNSW Australia, Australia
Demetre Daskalakis
New York City Department of Health and Mental Hygiene, United States
Nduku Kilonzo
National AIDS Control Council, Kenya
Matteo Cassolato
International HIV/AIDS Alliance
from HIV Research for Prevention 2016 on 19 October 2016 15:30-17:00
Symposium 05: Using ARVs and Antibodies for Long-Acting Prevention
One Person's Challenge Is Another Person's Opportunity: Antibody Mediated Prevention Is a Milestone Opportunity
Larry Corey
Fred Hutchinson Cancer Research Center, United States
Pipeline for Long-Acting Passive Prophylaxis: How and When Will We Choose?
Nina Russell
Bill and Melinda Gates Foundation
AAV and Other Novel Antibody Delivery Platforms
Frances Priddy
International AIDS Vaccine Initiative, United States
Engineering HIV Antibodies for Potency, Breadth and Half-life
John Mascola
National Institute of Allergy and Infectious Diseases, NIH, United States
from HIV Research for Prevention 2016 on 19 October 2016 15:30-17:00
Symposium 06: Effective Cellular Immune Reponses
Role of T Cells in Controlling HIV Infection
Andrew McMichael
University of Oxford, United Kingdom
Risk of HIV Acquisition Correlates Inversely with T Cell Polyfunctionality in Vaccine Efficacy Trials
Nicole Frahm
Fred Hutchinson Cancer Research Center, United States
Development of a Cytomegalovirus-based HIV Vaccine
Louis Picker
Oregon Health & Science University, United States
ADCC Immunity against HIV
Stephen Kent
University of Melbourne, Australia
from HIV Research for Prevention 2016 on 19 October 2016 15:30-17:00
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 13 of 13 from HIV Research for Prevention 2016